⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359140 | 1.00 | — | — | |
| SCHEMBL6851270 | 1.00 | — | — | |
| SCHEMBL8281598 | 0.84 | — | — | |
| SCHEMBL26451627 | 0.84 | — | — | |
| SCHEMBL13339152 | 0.82 | — | — | |
| SCHEMBL12825867 | 0.82 | — | — | |
| SCHEMBL1271049 | 0.82 | — | — | |
| SCHEMBL2907193 | 0.79 | — | — | |
| SCHEMBL14130634 | 0.78 | — | — | |
| SCHEMBL3692803 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611869-A | Heterocyclic pyrazine derivative and application thereof in preparation of SHP2 inhibitor | 山东大学 | 2023-01-17 | — | — | CN | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-20030125259-A1 | Octa- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-07-03 | — | — | US | claimed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | claimed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | claimed |
| CN-115611869-B | Heterocyclic pyrazine derivative and application thereof in preparation of SHP2 inhibitor | 山东大学 | 2024-08-09 | — | — | CN | disclosed |
| CN-115611869-A | Heterocyclic pyrazine derivative and application thereof in preparation of SHP2 inhibitor | 山东大学 | 2023-01-17 | — | — | CN | disclosed |
| EP-2840080-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | Fujifilm Corporation (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2177530-A1 | Octapeptide having antiangiogenic activity | Abbott Laboratories (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | disclosed |
| US-20030125259-A1 | Octa- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-07-03 | — | — | US | disclosed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | disclosed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | disclosed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | disclosed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | disclosed |